Tigerlily Foundation has partnered with Bristol Myers Squibb to expand access to clinical trials and address barriers that often limit participation among underrepresented communities, particularly young women of color affected by breast cancer. The collaboration is part of Tigerlily’s ONE in a MILLION campaign, an initiative focused on educating and empowering one million women about clinical research opportunities, including trials related to triple-negative breast cancer. By increasing awareness and improving access to information, the organizations aim to help more patients understand the role clinical trials can play in treatment and care decisions.
The initiative places a strong emphasis on building trust and improving communication around clinical research. Through educational outreach and patient engagement efforts, the partnership seeks to ensure that clinical trial discussions happen earlier in the treatment process and are presented in a patient-centered way. The organizations also aim to address common barriers to participation, such as lack of awareness, limited access to resources and historical underrepresentation in research, while fostering stronger connections between patients, healthcare providers and the broader research community.
Bristol Myers Squibb and Tigerlily Foundation say the collaboration reflects a shared commitment to improving equity in cancer research and care. Expanding diversity in clinical trials can lead to more representative data, stronger science and more effective treatments across patient populations. More broadly, the partnership highlights growing industry efforts to make clinical research more inclusive and accessible while supporting greater health equity in oncology.
Click here to read the original news story.
